NeoGenomics NEO Reportable Segment — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about NeoGenomics's reportable segment — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NeoGenomics's reportable segment — R&D?
- NeoGenomics (NEO) reported reportable segment — R&D of $8.46M in Q1 2026.
- How has NeoGenomics's reportable segment — R&D changed year-over-year?
- NeoGenomics's reportable segment — R&D decreased by 7.1% year-over-year, from $9.1M to $8.46M.
- What is the long-term trend for NeoGenomics's reportable segment — R&D?
- Over 3 years (2022 to 2025), NeoGenomics's reportable segment — R&D has grown at a 4.5% compound annual growth rate (CAGR), from $28.49M to $32.54M.
- What does reportable segment — R&D mean?
- Expenditures dedicated to the discovery and development of new diagnostic tests, technologies, or service enhancements within the segment. This reflects the company's commitment to long-term innovation and maintaining a competitive edge in genetic testing.